Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

From distinctly non-Xeno forms like the Deacon or the Neomorph to wildly different takes ... one of the best parts about ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

The North Chicago-based company announced today it entered into an option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and immune diseases. Neomorph ...

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...